Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 17, 2017

View Archived Issues

Spring Bank announces latest results from phase II inarigivir study

Investigational mineralocorticoid receptor antagonist KBP-5074 evaluated in phase I trial

Seres Therapeutics announces collaboration to test its microbiome therapies in cancer patients

OncoArendi Therapeutics patents arginase inhibitors

Bayer discovers new vasopressin receptor antagonists

FDA approves Genentech's Gazyva in new indication

GlaxoSmithKline discloses novel EZH2 inhibitors

Shanghai De Novo Pharmatech has presented TLR8 agonists

Amgen presents novel apelin receptor agonists

Sutent now approved in U.S. as adjuvant treatment for adults at high risk of recurrent RCC

Bayer and PeptiDream establish drug discovery collaboration

Evelo Biosciences and Mayo Clinic enter monoclonal microbial collaboration

Deerfield Management and Johns Hopkins announce creation of Bluefield Innovations

NICE recommends routine funding for Ibrance and Kisqali in England

Bayer presents preclinical data on the cardiac effects of BAY-1142524 after myocardial infarction

bb-2121 receives FDA breakthrough therapy and EMA PRIME designations

NIH grant supports MRSA osteomyelitis research at University of Rochester

FDA first to approve Hemlibra for hemophilia A

Thetis Pharmaceuticals obtains NIH grant to support development of ulcerative colitis drug

Bayer reports first-in-human data for BR-6819

FDA issues alert regarding Takeda's febuxostat for gout

Alnylam Pharmaceuticals begins rolling NDA submission for patisiran

FDA approves new formulation and pediatric indication for Tekturna

PIN Pharma begins phase I study of immune-modulator in solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 21, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 20, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...